Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Terminated
AstraZeneca
Phase 2
2008-06-30
This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of
aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the
evening vs. the FDC once daily in the morning and formoterol fumarate once in the evening vs.
formoterol fumarate twice daily. The study will assess pulmonary function and symptoms in
patients with moderate to severe COPD.
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
Completed
AstraZeneca
Phase 2
2009-12-01
The purpose of this study is to evaluate the efficacy of this multicenter, randomized,
double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study
comparing 2 fixed dose combinations (FDCs) of aclidinium bromide with formoterol fumarate or
with placebo, aclidinium bromide and formoterol fumarate, all administered twice a day (BID)
in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD)
beginning with a 2-week run-in period and with a 7-10 day washout each between treatment
period.
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
Completed
AstraZeneca
Phase 2
2010-02-01
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations
of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol
fumarate, all administered BID in patients with stable, moderate to severe COPD.
Every treatment period is 14-days long and there is a 7-days wash-out period in between them.
The trial starts with a run in phase of 10 to 17-days duration and it ends up with a follow
up contact 14-days after last treatment dose.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
